Placulumab (0.3, 1, 3 and 10 mg/kg; i.p.; twice weekly for 8 weeks) has effective anti-arthritis properties in Tg197 transgenic mouse model[1].
Pharmacokinetic (PK) parameters of Placulumab in cynomolgus macaques[1]
| Route | Dose (mg/kg) | Exposure AUC0-336 h (ng.h/mL) | Maximum concentration Cmax (ng/mL) | Time of maximum concentration tmax (h) | Elimination half-life t1/2 (h) | Clearance CL (mL/hr/kg) |
| Intravenous injection (Males) | 50 | 46000000 | 1320000 | 0.167 | 104 | 0.985 |
| Intravenous injection (Females) | 50 | 43300000 | 1020000 | 0.211 | 97.4 | 1.06 |
|
| Route | Dose (mg/kg) | Exposure AUC0-336 h (ng.h/mL) | Dose normalize exposure AUC0-336 h (norm) | Maximum concentration Cmax (ng/mL) | Time of maximum concentration tmax (h) | Elimination half-life t1/2 (h) |
| Subcutaneous injection (Males) | 0.5 | 676000 | 1350000 | 3190 | 50.0 | 120 |
| Subcutaneous injection (Females) | 0.5 | 445000 | 890000 | 2880 | 48.0 | 108 |
| Subcutaneous injection (Males) | 5 | 3940000 | 788000 | 22700 | 40.0 | 117 |
| Subcutaneous injection (Females) | 5 | 3840000 | 767000 | 23800 | 12.0 | 109 |
| Subcutaneous injection (Males) | 50 | 41600000 | 832000 | 272000 | 40.0 | 122 |
| Subcutaneous injection (Females) | 50 | 32300000 | 646000 | 212000 | 32.0 | 107 |
